Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

Nirav N. Shah, MD, Amrita Y. Krishnan, MD, Nina D. Shah, MD, John M Burke, MD, Jason M. Melear, MD, Alexander I. Spira, PhD MD FACP, Leslie L. Popplewell, MD FRCPA, Charalambos B. Andreadis, MD, Saurabh Chhabra, MD, Jeff P. Sharman, MD, Jonathan L. Kaufman, MD, Jonathon B. Cohen, MDMS, Ruben Niesvizky, MD, Thomas G. Martin, III, MD, Clifford DiLea, RPh, Pharm.D., Jason Kuriakose, Shannon L. Matheny, PhD, John P. Leonard, MD, Arturo Molina, MDMS, FACP

Blood (2019) 134 (Supplement_1): 5329.

https://doi.org/10.1182/blood-2019-122754

Published: 2019

Journal Articles

First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation

Adam D. Cohen, MD, Rakesh Popat, Suzanne Trudel, MD, Paul G Richardson, MD, Ed N. Libby, III, MD, Nikoletta Lendvai, MDPhD, Larry D. Anderson, Jr., MD PhD, Heather J. Sutherland, MD PhD, Stephen DeWall, Catherine E Ellis, Zangdong He, Jolly Mazumdar, Catherine Wang, Joanna B. Opalinska, MD PhD, Peter M. Voorhees, MD

Blood (2016) 128 (22): 1148.

https://doi.org/10.1182/blood.V128.22.1148.1148

Published: 2016

Journal Articles

Impact of Transporter Genes Polymorphisms in Standard Induction of Acute Myeloid Leukemia

Juan Eduardo Megías, PharmD, Pau Montesinos, MD, María José Herrero, PhD, Federico Moscardó, Virginia Bosó, PharmD, David Martínez-Cuadrón, MD, Luis Rojas, MD, Rebeca Rodríguez-Veiga, MD, Blanca Boluda, MD, Jesús Martínez, MD, Jaime Sanz, MD, Francisca López, MD, Isabel Cano, MD, Aima Lancharro, MD, Jose Cervera, MD, David Hervás, José Luis Poveda, PhD, Salvador F Aliño, PhD, Miguel Ángel Sanz, MD PhD

Blood (2015) 126 (23): 4842.

https://doi.org/10.1182/blood.V126.23.4842.4842

Published: 2015

Journal Articles

Long-Term Outcomes of Myeloablative Hematopoietic Cell Transplantation Using Total Body Irradiation Prior to Systemic Therapy

Cara L. Toretta, MS, Andrzej Niemierko, PhD, Erin Coughlin, Steven L. McAfee, MD, Bimalangshu R. Dey, MD, Karen K. Ballen, MD, Eyal C. Attar, MD, Yi-Bin A. Chen, MD, Thomas R. Spitzer, MD, Karen M. Winkfield, MD, PhD

Blood (2012) 120 (21): 4552.

https://doi.org/10.1182/blood.V120.21.4552.4552

Published: 2012

Journal Articles

The effect of Desferasirox in expression of Adhesion molecules in Neutrophils and Monocytes, in the Platelets Activacion and in the Atherothrombosis in Patients with Mielodisplastic Syndrome (MDS) and iron Overload.

Isabel Caparros, Regina Garcia-Delgado, Arturo Campos, Ana Rosell, Ma Paz Queipo de Llano, Santiago de la Torre, Gemma Ramirez, Laura Entrena, Eulogio Conde, MD, PhD, Santiago Del Castillo, MD, PhD

Blood (2009) 114 (22): 1346.

https://doi.org/10.1182/blood.V114.22.1346.1346

Published: 2009

Journal Articles

Rituximab and Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy May Be Feasible Options in Patients with Low-Grade Lymphoma of the Orbit.

Bita Esmaeli, MD, Barbara Pro, MD, M. Wayne Saville, MD, Peter McLaughlin, MD

Blood (2005) 106 (11): 4792.

https://doi.org/10.1182/blood.V106.11.4792.4792

Published: 2005

NARROW

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation

Impact of Transporter Genes Polymorphisms in Standard Induction of Acute Myeloid Leukemia

Long-Term Outcomes of Myeloablative Hematopoietic Cell Transplantation Using Total Body Irradiation Prior to Systemic Therapy

The effect of Desferasirox in expression of Adhesion molecules in Neutrophils and Monocytes, in the Platelets Activacion and in the Atherothrombosis in Patients with Mielodisplastic Syndrome (MDS) and iron Overload.

Rituximab and Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy May Be Feasible Options in Patients with Low-Grade Lymphoma of the Orbit.

Email alerts

ASH Publications

American Society of Hematology

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation

Impact of Transporter Genes Polymorphisms in Standard Induction of Acute Myeloid Leukemia

Long-Term Outcomes of Myeloablative Hematopoietic Cell Transplantation Using Total Body Irradiation Prior to Systemic Therapy

The effect of Desferasirox in expression of Adhesion molecules in Neutrophils and Monocytes, in the Platelets Activacion and in the Atherothrombosis in Patients with Mielodisplastic Syndrome (MDS) and iron Overload.

Rituximab and Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy May Be Feasible Options in Patients with Low-Grade Lymphoma of the Orbit.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only